Prostatic NeoplasmsPhase 3NCT00036556
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3 study testing Atrasentan in people with Prostatic Neoplasms, run by Abbott at 234 sites in 17 countries.
Trial summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer. Read more about this study
- Who is it for?
- Ages 19 years and older, men only
- Conditions the study is for
- Prostatic Neoplasms
- What is being tested?
- Atrasentan
- How many people
- 941 participants
- Where
- 234 sitesin 17 countries
- Study dates
- Jun 2001to not given
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have been diagnosed with prostate cancer.
- Have a rising PSA while on hormone therapy or following surgical castration.
Who cannot join
- Have evidence of distant metastatic disease on screening bone scan or CT scan.
- Have received cytotoxic chemotherapy.
- Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.
Trial locations and contacts
234 sites in 17 countries.
234 sites in 17 countries
United States94 sites
Albany Medical Center South Clinical Campus
Albany, New York, 12208-3499
UNM Medical Center
Albuquerque, New Mexico, 87131
Urologic Associates of Allentown
Allentown, Pennsylvania, 18103
Alaska Clinical Research Center, LLC
Anchorage, Alaska, 99508
Peachtree Hematology/Oncology Consultants
Atlanta, Georgia, 30309
Emory Clinic
Atlanta, Georgia, 30322
Sandy Springs Urology
Atlanta, Georgia, 30328
Dreyer Medical Clinic
Aurora, Illinois, 60506
South Fl Medical Research
Aventura, Florida, 33180
Johns Hopkins Oncology Center
Baltimore, Maryland, 21231-1000
Billings Oncology Associates
Billings, Montana, 59101
Massachusetts General Hospital
Boston, Massachusetts, 02114-2617
HemOnCare, PC
Brooklyn, New York, 11235
University Of Vermont
Burlington, Vermont, 05403
The University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina, 27599-7235
Blumenthal Cancer Center
Charlotte, North Carolina, 28203
Mckay Urology
Charlotte, North Carolina, 28204
Urology Specialists Of The Carolinas
Charlotte, North Carolina, 28207
Wyoming Research Foundation
Cheyenne, Wyoming, 82001
Northwestern University Medical School
Chicago, Illinois, 60611-3010
Progressive Care, S.C.
Chicago, Illinois, 60631
Christopher Ryan, MD
Chicago, Illinois, 60637-1470
Weiss Memorial Hospital
Chicago, Illinois, 60640
Robin V. Smith, MD
Chula Vista, California, 91910
University Of Cincinnati Medical Center
Cincinnati, Ohio, 45267-0589
Dept of Veteran's Affairs North Texas Healthcare System
Dallas, Texas, 75216
Ntouch Research Corporation
Dallas, Texas, 75230
The University Of TX SW Medical Center At Dallas
Dallas, Texas, 75390-9110
Urologic Associates, Pc
Davenport, Iowa, 52807
Atlanta Va Medical Center
Decatur, Georgia, 30033
Urology Associate, Pc
Denver, Colorado, 80210
Iowa Urology
Des Moines, Iowa, 50309
Oregon Urology Specialists
Eugene, Oregon, 97401
Evanston Hospital Kellogg Cancer Center
Evanston, Illinois, 60201
Welborn Clinic
Evansville, Indiana, 47713
Welborn Clinic -East
Evansville, Indiana, 47714-0981
Clinical Physiology Associates
Fort Myers, Florida, 33916
Urology Associate Of Central California
Fresno, California, 93720
South Valley Medical Plaza
Gilroy, California, 95020-3535
Michigan Medical Urology
Grand Rapids, Michigan, 49503
Drs. Werner, Murdock, & Francis, Pa Urology Assoc.
Greenbelt, Maryland, 20770
The Urology Center
Greensboro, North Carolina, 27401
The Medical Oncology Group
Gulfport, Mississippi, 39501
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Urology Centers Of Alabama
Homewood, Alabama, 35205
Mississippi Center For Clinical Research, LLC
Jackson, Mississippi, 39216
Kansas University Medical Center
Kansas City, Kansas, 66160-7390
San Diego Urology Center
La Mesa, California, 91942
South Orange County Medical Research Center
Laguna Hills, California, 92653
Urological Associates Of Lancaster
Lancaster, Pennsylvania, 17604-3200
Arkansas Urologial Associates, PA
Little Rock, Arkansas, 72205
UCLA School of Medicine
Los Angeles, California, 90095-1738
University of TN - Memphis
Memphis, Tennessee, 38104
Midwest Research Specialists, LLC
Milwaukee, Wisconsin, 53209
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Urology Associates
Nashville, Tennessee, 37209
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-2765
Advanced Research Institute
New Port Richey, Florida, 34652
Beth Israel Medical Center
New York, New York, 10003
NYU Medical Center
New York, New York, 10016
Nyack Hospital
Nyack, New York, 10960
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7860
VA Palo Alto
Palo Alto, California, 94304
Albert Einstein Medical Center
Philadelphia, Pennsylvania, 19141
University Of Pittsburgh
Pittsburgh, Pennsylvania, 15232
Multimed Research
Providence, Rhode Island, 02905
Nevada Urology Associate
Reno, Nevada, 89509
Virginia Urology Center
Richmond, Virginia, 23230
Mayo Clinic
Rochester, Minnesota, 55905
Mid Atlantic Clinical Research
Rockville, Maryland, 20850
Michigan Institute Of Urology, Pc
Saint Clair Shores, Michigan, 48081
Lakeside Urology, PC
Saint Joseph, Michigan, 49085
St. Joseph Oncology
Saint Joseph, Missouri, 64507
Anthony Middleton, M.D.
Salt Lake City, Utah, 84102
Western Urological Clinic
Salt Lake City, Utah, 84107
Uthscsa
San Antonio, Texas, 78229
Hillcrest Urological Medical Group, Inc.
San Diego, California, 92103
Urology Associates Of San Luis Obispo
San Luis Obispo, California, 93405
Pacific Clinical Research
Santa Monica, California, 90404
Dattoli Cancer Center
Sarasota, Florida, 34237
Urology Treatment Center
Sarasota, Florida, 34239
Seattle Urological Associates
Seattle, Washington, 98104
University Of Washington School Of Medicine
Seattle, Washington, 98109-1023
Jeffrey Frankel, M.D.
Seattle, Washington, 98166-3059
Regional Urology
Shreveport, Louisiana, 71106
LSUHSC
Shreveport, Louisiana, 71130
Washington University
St Louis, Missouri, 63110
Madigan Army Medical Center
Tacoma, Washington, 98431
Southeastern Urological Center, P.A.
Tallahassee, Florida, 32308
Scott & White Memorial Hospital
Temple, Texas, 76508
Western Clinical Research, Inc.
Torrance, California, 90505-4763
Advanced Clinical Trials
Tucson, Arizona, 85712
Urologic Specialists Of Oklahoma, Inc.
Tulsa, Oklahoma, 74104-5433
Center for Urologic Care
West Reading, Pennsylvania, 19611
Canada32 sites
The Male Health Centres
Barrie, Ontario, L4M 4S5
The Urology Resource Centre
Burlington, Ontario, L7S 1V2
Tom Baker Cancer Center
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Service Radio-Oncologie, Chus
Fleurimont, Quebec, J1H 5N4
Professional Corporation
Fredericton, New Brunswick, E3B 5B8
Northeastern Ontario Regional Cancer Centre
Greater Sudbury, Ontario, P3E 5J1
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, B3H 2Y9
Hamilton & District Urology Association
Hamilton, Ontario, L8N 1T8
Wilson Urology
Kelowna, British Columbia, V1Y 2H4
Valley Professional Centre
Kentville, Nova Scotia, B4N 4K9
Kingston General Hospital
Kingston, Ontario, K7L 2V7
Probidity Medical Research
Kitchener, Ontario, N2M 5N6
London Health Sciences Centre
London, Ontario, N6A 4G5
Quest Clinical Trials
Markham, Ontario, L6B 1A1
Hopital Notre-Dame
Montreal, Quebec, H2L 4M1
Royal Victoria Hospital
Montreal, Quebec, H3A 1A1
Walk-In Clinic
North Bay, Ontario, P1B 4Z2
Jack Barkin, M.D.
North York, Ontario, M6A 3B5
The Male Health Centres
Oakville, Ontario, L6H 3P1
Ottawa Hospital Civic Campus
Ottawa, Ontario, K1Y 4E9
Ultramed
Pointe-Claire, Quebec, H9R 4S3
Chuq Pavillon Hotel-Dieu
Québec, Quebec, G1R 2J6
Peter Lau, MD
Saskatoon, Saskatchewan, S7K 3H3
Advanced Male Fertility Clinic
Scarborough Village, Ontario, M1S 4V5
Dr. Cal Andreou
Surrey, British Columbia, V3V 1N1
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Vancouver Hospital & Health Sciences Centre
Vancouver, British Columbia, V5Z 3J5
Dr. P. J. Pommerville, Inc.
Victoria, British Columbia, V8T5G1
Dr. Gary Steinhoff, Clinical Research
Victoria, British Columbia, V8V 3N1
Abbott Clinic
Winnipeg, Manitoba, R3C 1V8
United Kingdom20 sites
Clatterbridge Centre For Oncology
Bebington, WIRRAL, CH63 4JY
St Lukes Hospital
Bradford, West Yorkshire, BD5 0NA
Southmead Hospital
Bristol, BS10 5NB
Addenbrookes Hospital
Cambridge, CB2 2QQ
St Richard'S Hospital
Chichester, PO19 4SE
Leighton Hospital
Crewe, CW1 4QJ
Western General Hospital
Edinburgh, Scotland, EH4 2XU
Royal Devon And Exeter Hospital
Exeter, Devon, EX2 5DW
Gartnavel General Hospital
Glasgow, G12 0YN
Glasgow Royal Infirmary
Glasgow, G31 2ER
Northwick Park Hospital
Harrow, Middlesex, HA1 3UJ
St Batholomew'S Hospital
London, EC1A 7BE
Royal Free Hospital
London, NW3 2QG
Clinical Research Centre - St Georges Hospital
London, SW17 0QT
Hope Hospital
Salford, M6 8HD
Royal Hallamshire Hospital
Sheffield, S10 2JF
Southampton General
Southampton, SO16 6YD
Lister Hospital
Stevenage, Hertfordshire, SG1 4AB
The Institute Of Cancer Research - Royal Marsden Hospital
Sutton, Surrey, SM2 5PT
Taunton And Somerset Hospital
Taunton, Somerset, TA1 5DA
Germany12 sites
Allgemeines Krankenhaus Urologie
Celle, 29223
Universitätsklinikum Urologie
Essen, 45147
Universitätsklinkum
Freiburg im Breisgau, 79106
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246
Allgemeines Krankenhaus Barmbek
Hamburg, 22291
Klinik Und Poliklinik für Urologie und Kinder
Homburg / SAAR, 66421
Universitätsklinikum Lübeck Urologie
Lübeck, 23538
Universitätsklinikum Mannheim
Mannheim, 68135
Urologische Klinik Und Poliklinik Grosshadern
München, 81377
Klinikum Rechts Der Isar
München, 81675
Universitat Ulm
Ulm, 89070
Klinikum Wuppertal GmbH
Wuppertal, 42283
France11 sites
Hôpital D´Auxerre
Auxerre, 89000
Hopital Intercommunal
Créteil, Cedex, 94010
Hôpital Henri Mondor
Créteil, 94010
Hôpital Salvator
Marseille, Cedex, 9 13274
Hôpital Pasteur
Nice, Cedex, 3 06202
Hôpital Cochin
Paris, Cedex 14, 75679
Hôpital Saint Louis
Paris, Cedex, 10 75475
Hopital Bichat Claude Bernard
Paris, 75018
Centre Hospitalier Rene Dubos
Pontoise, Cedex, 95303
Hopital De Pontchaillou
Rennes, Cedex, 35033
Hopital De Rangueil
Toulouse, Cedex, 31043
Spain9 sites
Hospital Juan Canalejo
A Coruña, 15006
Hospital de la Ribera
Alcira (Valencia), 46600
Hospital Vall D'Hebron
Barcelona, 08035
Hospital de Galdakao
Galdakao-Vizcaya, 48960
Clinica Puerta De Hierro
Madrid, 28035
Hospital 12 De Octubre
Madrid, 28041
Hospital Carlos Haya
Málaga, 29009
Hospital Marques De Valdecilla
Santander, 39008
Instituto Valenciano De Oncologia
Valencia, 46009
Australia8 sites
Repatriation General Hospital
Daws Park, South Australia, 5041
Peter Maccallum Cancer Institute
East Melbourne, Victoria, 3002
Royal Brisbane Hospital
Herston, Queensland, 4029
Bayside Urology
Mentone, Victoria, 3194
Royal Melbourne Hospital
Parkville, Victoria, 3050
Prince Of Wales Hospital
Randwick, New South Wales, 2031
Westmead Public Hospital
Westmead, New South Wales, 2145
Princess Alexandra Hospital
Woolloongabba, QLD 4102
Belgium7 sites
A.Z. Middelheim
Antwerp, 2020
A Z St Jan
Bruges, 8000
University Hospital Erasme
Brussels, 1070
Uz Gent
Ghent, 9000
Private Practice Dr.Vekemans
Hasselt, 3500
C.H.U. Liege
Liège, 4000
St-Elisabeth Ziekenhuis
Turnhout, 2300
South Africa7 sites
University Of Stellenbosch
Cape Town
University Of Natal - Nelson R Mandela School of Medicine
Durban, 4013
Kenridge St Joseph Wingl
Parktown, 2010
Mediclinic Hospital
Petermaritzburg, 3201
Medi-Clinic Hospital
Pietermaritzburg, 3201
Medical Centre
Pietermaritzburg, 3201
Pretoria Urology Hospital
Pretoria, 0083
Italy6 sites
Clinica Urologica I - Università di Bari
Bari, 70124
Istituto Nazionale per la Ricerca sul Cancro -IST
Genoa, 16132
Istituto Europeo di Oncologia
Milan, 20141
Clinica Urologica - Università Di Milano
Milan, 20142
Istituto di Urologia
Padova, 35128
Policlinico G. B. Rossi
Verona, 37134
Netherlands6 sites
Amc
Amsterdam, 1105 AZ
Rijnstate Hospital
Arnhem, 6815 AD
Medisch Spectrun Twente
Enschede, 7500 KA
Atrium Heerlen
Heerlen, 6401 CX
University Hospital Rotterdam
Rotterdam, 3015 GD
St Franciscus Gasthuis
Rotterdam, 3045 PM
Poland6 sites
Samodzielny Publiczny ZOZ
Bydgoszcz, 85-168
Katedra i Klinika Urologii - Akademia Medyczna w Gdansku
Gdansk, 80-742
Specjalistyczny Szpital Urologiczny
Katowice, 40-073
Szpital Kliniczny Dzieciatka Jezus
Warsaw, 02-034
Instytut im. Marii Sklodowskiej-Curie
Warsaw, 02-781
Akademia Medyczna we Wroclawiu
Wroclaw, 50-043
Sweden6 sites
Sahlgrenska University Hospital
Gothenburg, 41345
Linkoping University Hospital
Linköping, 501 85
Lund University Hospital
Lund, 221 85
Malmo University Hospital MAS
Malmö, 205 02
Karolinska Hospital
Stockholm, 171 76
Uppsala University Hospital
Uppsala, 751 85
Greece3 sites
'Alexandra' Hospital
Athens, 115 27
Pe.Pa.G.N.I Hospital
Heraklion, 711 10
G. Genimatas Hospital
Thessaloniki, 546 35
Ireland3 sites
Tallaght Hospital
Dublin, 24
St Vincent'S Hospital
Dublin, 4
Mater Misericordiae Hospital
Dublin, 7
Austria2 sites
A. Ö. Krankenhaus Mistelbach
Mistelbach, 2130
Klinik fur Urologie der Universitat Wien
Vienna, A-1090
New Zealand2 sites
Canterbury Urology Research Trust
Christchurch
Promed Urology Ltd.
Tauranga
About this study
Official title: A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
- Conditions
- Prostatic Neoplasms
- Being tested
- Atrasentan
- Keywords
- Hormone-Refractory Prostate Cancer
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AtrasentanDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer.
Measured: Every 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2002 (estimated)
- Study startJun 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostatic NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 941 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abbott
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Gary Gordon, M.D., Study director, Abbott
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00036556
- Sponsor's protocol ID
- M00-244
- Status last verified
- Aug 2007
- First submitted
- 10 May 2002
- Last updated
- 15 Aug 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- ClinicalTrials.gov ID
- NCT00036556
- Acronym / sponsor ID
- M00-244
- Conditions
- Prostatic Neoplasms
- Keywords
- Hormone-Refractory Prostate Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 941 participants (actual)
- Lead sponsor
- AbbottIndustry (pharma, biotech, devices)
- Study start
- Jun 2001
- First posted
- 13 May 2002 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 19 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Have been diagnosed with prostate cancer.
- Have a rising PSA while on hormone therapy or following surgical castration.
Key exclusion criteria (3 listed)
- Have evidence of distant metastatic disease on screening bone scan or CT scan.
- Have received cytotoxic chemotherapy.
- Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atrasentan | Drug | – |
Primary outcome
Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer.
Time frame: Every 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2007.
Related trials for Prostatic Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gary Gordon, M.D. study director
Abbott
234 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Atrasentan in people with Prostatic Neoplasms, run by Abbott at 234 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 234 sites in United States, Canada, United Kingdom, Germany, France and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer. (time frame: Every 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2007.